AbbVie Inc. $ABBV Position Trimmed by Vaughan David Investments LLC IL

Vaughan David Investments LLC IL cut its stake in AbbVie Inc. (NYSE:ABBV) by 1.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 332,800 shares of the company’s stock after selling 3,664 shares during the quarter. AbbVie makes up approximately 1.6% of Vaughan David Investments LLC IL’s portfolio, making the stock its 9th largest holding. Vaughan David Investments LLC IL’s holdings in AbbVie were worth $76,041,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in shares of AbbVie by 0.3% during the 3rd quarter. Vanguard Group Inc. now owns 177,747,261 shares of the company’s stock worth $41,155,601,000 after buying an additional 448,554 shares during the last quarter. Public Sector Pension Investment Board increased its holdings in shares of AbbVie by 17.0% during the 3rd quarter. Public Sector Pension Investment Board now owns 1,044,690 shares of the company’s stock worth $241,888,000 after buying an additional 151,644 shares during the last quarter. Thornburg Investment Management Inc. increased its holdings in shares of AbbVie by 25.5% during the 3rd quarter. Thornburg Investment Management Inc. now owns 401,760 shares of the company’s stock worth $93,024,000 after buying an additional 81,625 shares during the last quarter. Channing Capital Management LLC increased its holdings in shares of AbbVie by 10.5% during the 3rd quarter. Channing Capital Management LLC now owns 55,647 shares of the company’s stock worth $12,885,000 after buying an additional 5,302 shares during the last quarter. Finally, Procyon Advisors LLC increased its holdings in shares of AbbVie by 19.9% during the 4th quarter. Procyon Advisors LLC now owns 32,752 shares of the company’s stock worth $7,484,000 after buying an additional 5,427 shares during the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

AbbVie Stock Performance

NYSE:ABBV opened at $225.04 on Friday. The stock has a market capitalization of $397.60 billion, a P/E ratio of 110.86, a PEG ratio of 0.69 and a beta of 0.32. The company has a 50 day moving average price of $210.80 and a 200 day moving average price of $219.01. AbbVie Inc. has a fifty-two week low of $181.73 and a fifty-two week high of $244.81.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, topping analysts’ consensus estimates of $2.59 by $0.06. The firm had revenue of $15 billion during the quarter, compared to analysts’ expectations of $14.72 billion. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The firm’s quarterly revenue was up 12.4% on a year-over-year basis. During the same quarter last year, the company posted $2.46 EPS. Research analysts forecast that AbbVie Inc. will post 14.3 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on ABBV shares. BMO Capital Markets restated an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Piper Sandler raised their price target on shares of AbbVie from $294.00 to $298.00 and gave the stock an “overweight” rating in a report on Thursday, May 14th. Canaccord Genuity Group raised their price target on shares of AbbVie from $262.00 to $265.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. Wall Street Zen downgraded shares of AbbVie from a “strong-buy” rating to a “buy” rating in a report on Sunday, June 7th. Finally, Guggenheim restated a “buy” rating and set a $249.00 price target on shares of AbbVie in a report on Friday, May 1st. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, AbbVie has an average rating of “Moderate Buy” and a consensus price target of $253.43.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie said new Phase 3 data for venetoclax in first-line chronic lymphocytic leukemia showed durable, long-term treatment outcomes, supporting confidence in the drug’s commercial runway and oncology pipeline. Article link
• Positive Sentiment: AbbVie’s Skyrizi and Rinvoq continue to drive top-line growth, with strong first-quarter performance and new indications helping lift 2026 sales expectations. Article link
• Positive Sentiment: One article highlighted that promising clinical updates could help AbbVie fund future dividend growth, reinforcing the stock’s appeal for income-focused investors. Article link
• Neutral Sentiment: AbbVie was also mentioned in market commentary and “final trades” segments, which can increase attention but do not by themselves change the company’s fundamentals. Article link
• Negative Sentiment: AbbVie received a Complete Response Letter for its fast-acting neurotoxin TrenibotE, with the FDA citing manufacturing issues; while no safety or efficacy concerns were raised, the setback delays a potentially important aesthetics product. Article link

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.